1 / 58

Adrenocorticosteroids and Adrenocortical Antagonists

Adrenocorticosteroids and Adrenocortical Antagonists. Adrenal Gland. Adrenal cortex – mineralocorticoids, glucocorticoids, adrenal androgens (androstenedione and dehydroepiadrosterone) Adrenal medulla - catecholamines. Adrenal Cortex.

lew
Download Presentation

Adrenocorticosteroids and Adrenocortical Antagonists

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. AdrenocorticosteroidsandAdrenocortical Antagonists

  2. Adrenal Gland • Adrenal cortex – mineralocorticoids, glucocorticoids, adrenal androgens (androstenedione and dehydroepiadrosterone) • Adrenal medulla - catecholamines

  3. Adrenal Cortex • Outer zone (zona glomerulosa) – secretes mineralocorticoids - receptors for angiotensin II and express aldosterone synthase; do not atrophy • Inner zone (zona fasciculata and reticularis) – secrete glucocorticoids and adrenal androgens - expresses 17α-hydroxylase and 11β-hydroxylase; results in atrophy

  4. ACTH • a peptide of 39 amino acids • amino acids 15 – 18: high affinity binding • amino acids 6 – 10: receptor activation • synthesized from pro-opiomelanocortin (POMC)

  5. ACTH • Stimulates the synthesis and release of adrenocortical hormones • Human ACTH – G-protein coupled receptor family → activates adenyl cyclase → ↑ intracellular cyclic AMP (2nd messenger for most steroidogenesis)

  6. Regulation of ACTH secretion • Hypothalamic – Pituitary – Adrenal axis (HPA axis) - 3 levels of regulation: 1. diurnal rhythm in basal steroidogenesis 2. negative feedback regulation 3. marked increases in steroidogenesis in response to stress

  7. Steroid hormone production • rate limiting step – conversion of cholesterol to pregnanolone • sources of cholesterol: circulating cholesterol (LDL), cholesterol esterase, de novo biosynthesis

  8. Adrenal Cortex • Produce and releases natural adrenocortical hormones • Uses: a. diagnosis and treatment of disorders of adrenal function b. treatment of inflammatory and immunologic disorders

  9. Adrenocorticosteroids Classification: A. Mineralocorticoids B. Glucocorticoids C. Gonadal Androgens

  10. A. Glucocorticoids Naturally-occurring: Cortisol Kinetics: 10-20 mg daily; circadian rhythm; bound to CBG (90%), albumin (5%); t ½ =60-90 mins.; liver; 1/3 excreted as dihydroxyketone metabolites

  11. B. Mineralocorticoids 1. Aldosterone – zona glomerulosa - promotes reabsorption of Na+ from the distal convoluted tubules and proximal collecting tubules; loosely coupled with K+ and H+ ions - secreted at a rate of 100-200ug/d; t ½ 15-20mins; excreted in the urine as tetrahydroaldosterone and 3-oxo-glucoronide

  12. 2. Deoxycortisone (DOC) – serves as precursor of aldosterone 3. Fludrocortisone – most widely used; both mineralocorticoid and glucocorticoid activity

  13. C. Adrenal Androgens - dehydroepiandrosterone (DHEA) and androstenedione - they do not stimulate or support major androgen dependent pubertal changes in humans) - used in SLE and women with adrenal insufficiency

  14. Dynamics: MOA: bind to cytosol receptors (steroid receptor complex) alters gene expression by binding to glucocorticoid-response element (GREs)

  15. Physiologic effects Carbohydrate and protein metabolism: protect glucose-dependent tissues from starvation ( gluconeogenesis, glycogen synthesis) periphery: ↓glucose utilization, ↑protein breakdown (amino acids), activate lipolysis (glycerol) catabolic effects: decrease muscle mass, atrophy of lymphoid tissue, negative nitrogen balance, thinning of the skin

  16. Physiologic effects (cont.): • Lipid metabolism: redistribution of body fat (buffalo hump, moon facies, supraclavicular area with loss of fat in the extremities) induce lipolysis in adipocytes ( FFA) • Electrolyte and water balance: enhances the reabsorption of Na (aldosterone) renal excretion of free water and interferes with Ca uptake, while there is ↑Ca excretion by the kidneys (glucocorticoids)

  17. Physiologic effects (cont.) • Cardiovascular system: - mineralocorticoid-induced changes – hpn - enhance vascular reactivity to other vasoactive substances • Skeletal muscle: normal function (steroid myopathy) • CNS: neurosteroids (regulate neuronal excitability)

  18. Physiologic effects: • Formed elements of blood: minor effects on hgb and erythrocyte production; affect circulating WBC (Addison’s: lymphocytosis, ↑ mass of lymphoid tissue) • Anti-inflammatory and Immunosuppressive action • alter immune response of lymphocytes - ↓release of vasoactive and chemoattractive factors, - diminished secretion of lipolytic and proteolytic enzymes - decreased extravasation of leukocytes to injury - decreased fibrosis - effect on cytokine production

  19. Other effects: ↑amounts – insomnia, euphoria, depression, pseudomotor cerebri ↓amounts – psychiatric depression large doses – peptic ulcer, promote fat distribution; vit D antagonist on Ca absorption; ↑ # of platelets and RBCs absence – impaired renal function fetal lung effects

  20. Classification of Adrenocorticosteroids I. Short to medium-acting glucocorticoids: a. Hydrocortisone (cortisol) b. Cortisone c. Prednisone d. Prednisolone e. Methylprednisolone f. Meprednisone

  21. II. Intermediate-acting glucocorticoids a. Triamcinolone b. Paramethasone c. Fluprednisolone III. Long-acting glucocorticoids a. Betamethasone b. Dexamathasone IV. Mineralocorticoids a. Fludrocortisone b. desoxycorticosterone acetate

  22. Topical steroids

  23. Therapeutic principles • Dose selection by trial & error; Needs frequent evaluation • Single dose: No harm • Few days therapy unlikely to be harmful • Incidence of side effects related to duration of therapy • Use is only palliative (except replacement therapy) • Inter-current illness: Dose is doubled • Abrupt cessation of prolonged high dose leads to adrenal insufficiency (contraindicated)

  24. Addison described :           . general languor and debility          . remarkable feebleness of the heart's action          . irritability of the stomach          . peculiar change of the color of the skin 

  25. Synthetic Steroids Kinetics: source – cholic acid (cattle) or steroid sapogenins (diosgenin, hecopenin); absorption: oral, IV, IM, sites of local administration prolonged effects: occlusive dressing, large areas – may cause suppression of HPA axis

  26. Kinetics (cont.) • Transport: 90% bound to CBG (transcortin – high affinity but low total binding capacity) and albumin (low affinity but high binding capacity) 10% unbound • Metabolism –liver • Excretion - kidneys

  27. Therapeutic Uses: A. Replacement Therapy 1. Adrenal Insufficiency a. Acute adrenal insufficiency ssx: GIT symptoms, dhn, hypoNa, hyperK, weakness, lethargy, hypotension cause: disorder of the adrenal abrupt withdrawal of glucocorticoids at high doses or prolonged use mgt: IV : D5 0.3%NaCl solution Monitor for fluid overload Hydrocortisone (cortisol) 100mg bolus, ffed by 100mg every 8 hrs. ; once stable, may give 25mg IM hydrocortisone every 6-8hrs.; thereafter, same mgt with chronic adrenal insufficiency

  28. 1. Adrenal Insufficiency (cont.) b. Chronic Adrenal Insufficiency (Addison’s disease) ssx:hyperpigmentation, wt. loss, inability to maintain fasting blood sugar, weakness, fatigue, hypotension cause: primary adrenal insufficiency, tuberculosis mgt: Hydrocortisone 20-30mg/day BID Fludrocortisone acetate 0.05 – 0.2mg/day (valuable indicator of adequate replacement: disappearance of hyperpigmentation and resolution of electrolyte abnormalities) -monitor plasma ACTH levels or measure urinary free cortisol; dosage adjustments for stress

  29. Therapeutic Uses (cont.)2. Adrenocortical hypo- and hyperfunctioning a. Congenital Adrenal Hyperplasia ssx: after puberty with infertility, hirsutism, amenorrhea and acne; female pseudohermaphroditism; accelerated linear growth but height at maturity is reduced; salt wasters – CV collapse (volume depletion) cause: Genetic disorder; activity of enzymes required for the biosynthesis of corticosteroid is deficient (21 β hydroxylase) mgt: 1st seen as acute adrenal crisis oral hydrocortisone 0.6mg/kg/day BID or TID fludrocortisone acetate 0.05-0.2mg/day treatment in-utero: mothers at risk – glucocorticoid therapy is initiated before 10 weeks gestation ffed by genotyping and sex determination

  30. b. Cushing’s syndrome cause: pituitary adenoma, tumors of the adrenal gland ssx: round, phletoric face, truncal obesity, muscle wasting, thinning, purple striae and easy bruising of the skin, poor wound healing, osteoporosis mgt: surgery hydrocortisone 300 mg IV on the day of the surgery, then maintenance oral dose

  31. B. Stimulation of fetal lung maturation –betamethasone 12mg ffed by 12mg 18-24 hrs. later C.Nonendocrine Diseases 1. Rheumatic disorders – suppress the disease and minimize resultant tissue damage mgt: prednisone 10 mg/kg/day (taper thereafter by decreasing 1mg/kg/day every 2-3 wks) intraarticular injection: triamcinolone acetonide osteoarthritis : intraarticular injections with interval of 2-3 mos. to minimize complications

  32. C. Non-Endocrine Diseases (cont.) 2. Renal Disorders – nephrotic syndrome mgt: prednisone: 1-2 mg/kg x 6 wks, ffed. by gradual tapering over 6-8 wks or alternate-day therapy (diminished proteinuria in 85% pts in 2-3 wks and 95% pts will have remission in 3 mos. - membranous glomerulonephritis mgt: alternate-day prednisone 8-10 wks ffed by 1-2 month period of tapering

  33. C. Non-Endocrine Diseases (cont.) 3. Allergic Disease – epinephrine 0.5ml of a 1:1000 solution IM or SQ, repeated every 15 mins up to 3 doses is needed (anaphylaxis) - onset of action of glucocorticoid is delayed

  34. C. Non-Endocrine Diseases (cont.) 4. Bronchial Asthma – role of inflammation in the immunopathogenesis - onset of action is delayed for 6 – 12 hrs. mgt: IV methylprednisolone 60-120mg initially ffed. by oral prednisone 40-60mg daily as the attack resolves inhaled steroids – reduces bronchial hyperreactivity with les suppression of adrenal function (dysphonia or oropharyngeal candidiasis)

  35. C. Non-Endocrine Diseases (cont.) 5. Infectious Disease – P. carinii pneumonia – increases oxygenation and decreases the incidence of respiratory failure and mortality H. influenzae type b meningitis – decrease the long-term neurological impairment 6. Ocular disease – 0.1% dexamethasone - C/I: herpes simplex keratitis (clouding of the cornea) , glaucoma

  36. C. Non-Endocrine Diseases (cont.) 7. Skin diseases – inflammatory dermatoses 8. GIT diseases – inflammatory bowel disease 9. Hepatic diseases – prednisolone – 80% histologic remission in pts. with chronic, active hepatitis 10. Malignancies – ALL, lymphomas 11. Cerebral edema 12. Miscellaneous dis – Sarcoidosis (induce remission), thrombocytopenia (decrease bleeding tendency), organ transplantation, spinal cod injury

More Related